modelPimozide
Extends from Pharmacolibrary.Drugs.ATC.N.N05AG02.
Information
| name: | Pimozide | |
| ATC code: | N05AG02 | route: | oral |
| compartments: | 1 | |
| dosage: | 4 | mg |
| volume of distribution: | 6 | L |
| clearance: | 0.18 | L/h/kg |
| other parameters in model implementation | ||
Pimozide is a typical antipsychotic drug of the diphenylbutylpiperidine class, primarily used in the treatment of chronic psychotic disorders such as Tourette's syndrome and schizophrenia. Although approved for use, it is less commonly prescribed today due to the risk of severe side effects, such as QT prolongation and arrhythmias.
Pharmacokinetics
Pharmacokinetic parameters reported in healthy adult volunteers following oral administration.
References
Sallee, FR, et al., & Perel, JM (1987). Pharmacokinetics of pimozide in adults and children with Tourette's syndrome. Journal of clinical pharmacology 27(10) 776–781. DOI:10.1002/j.1552-4604.1987.tb02995.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/3480904
Yonkers, KA, et al., & Blumenthal, S (1992). Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. The American journal of psychiatry 149(5) 587–595. DOI:10.1176/ajp.149.5.587 PUBMED:https://pubmed.ncbi.nlm.nih.gov/1575248
Migdalof, BH, et al., & Janssen, PA (1979). Penfluridol: a neuroleptic drug designed for long duration of action. Drug metabolism reviews 9(2) 281–299. DOI:10.3109/03602537908993895 PUBMED:https://pubmed.ncbi.nlm.nih.gov/385274
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)